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Since the characterization of the genome of the
hepatitis E virus (HEV) in 1990, a large genetic
diversity has been described. A single real-time
reverse transcription (RT)-PCR assay with Taq-
Man1 technology has been validatedwhich uses
only one set of primers and probe within the
ORF2HEV region (nt 5207–5292) for the detection
and quantiﬁcation of the fourmajor genotypes of
HEV. This assay proved to be as efﬁcient as the
conventional RT-PCRmethodology for the detec-
tion of HEV in clinical samples testing positive
previously. The real-time RT-PCR and conven-
tional RT-PCR were performed comparatively on
60 pairs of sera and stools collected during a
recent outbreak of hepatitis E in Darfur. The real-
time RT-PCR assay was 10- to 100-fold sensitive
than for conventional RT-PCR assays used in this
study with a range quantitation from 1.8101 to
7.2 103RNAcopies/ml in clinical samples (serum
and stools). J. Med. Virol. 78:1076–1082,
2006.  2006 Wiley-Liss, Inc.
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INTRODUCTION
The genetic heterogeneity of hepatitis E virus (HEV)
has been well documented, and HEV isolates have been
classiﬁed into from fourmajor to at least nine genotypes
according to partial or full-length sequences: genotype 1
(Asian and African strains), genotype 2 (the prototype
Mexican strain and a few African strains), genotype 3
(strains fromsporadic cases in industrialized countries),
and genotype 4 (strains from sporadic cases in China,
Japan, and Taiwan) [Schlauder and Mushahwar, 2001;
Emerson and Purcell, 2003; Mansuy et al., 2004a]. The
molecular detection of the various HEV genotypes by
conventional reverse transcription (RT)-PCR currently
involves the use of various speciﬁc sets of primers
designed to amplify conserved regions within ORF1,
ORF2, and ORF3 [Tam et al., 1991; Hsieh et al., 1998;
Schlauder andMushahwar, 2001]. A universal RT-PCR
assay able to detect divergent strains of HEV was
developed recently and validated, but this technique is
based on a conventional RT-PCR [Cooper et al., 2005].
Real-time RT-PCR assays using SYBR Green dye or
TaqMan1 probes have been developed successfully for
the detection of HEV specimens, but these researchers
did not report examining their assay with the various
HEV genotypes in circulation [Orru et al., 2004]. In
addition, SYBR Green dye binds to double-stranded
nucleic acids generated during the ampliﬁcation, allow-
ing sensitive detection of products in real time. How-
ever, unlike PCR assays using internal ﬂuorescent
probes, this approach does not avoid the quantitation
of non-speciﬁc ampliﬁcation products [Ririe et al., 1997].
The development of a broadly reactive real-time assay
using the TaqMan1 chemistry is preferable to other
ﬂuorescent assay types based on lower relative cost,
relative ease of design, and the higher speciﬁcity of the
probe-based TaqMan1 assay versus non-probe ap-
proaches like SYBR Green. Two real-time RT-PCR
assays using TaqMan1 chemistry have been described.
Mansuy et al. [2004a] described a method sensitivity of
1,000 copies/ml of serumsample, but didnot enhance the
ability of the assay to detect multiple HEV genotypes.
The second assay [Jothikumar et al., 2006] able to detect
all HEVgenotypeswith high speciﬁcitywas a TaqMan1
assay validated fromHEV isolates. But no quantitation
of the viral load from a large number of human and
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animal clinical samples has been reported. Conse-
quently, the aim of this study was to develop a single
real-time LightCycler RT-PCR assay using TaqMan1
probe technology to detect any of the four major geno-
types of HEV and to quantify HEV in clinical samples,
sera, and stools.
MATERIALS AND METHODS
HEV Strain Alignment and Design of
Primers and Probe
Twenty-six full-length human and swine HEV se-
quences including strains representative of the four
major genotypes were aligned with the multiple
sequence editor CLUSTALX (1.82). The Genbank
accession numbers of the complete genomes are listed
in Figure 1. Local alignments were performed in several
regions using all complete and partial HEV sequences
available at the time of the study. The sequences were
manipulated using DNA strider 1.3.6 (CEA). Homo-
logous sequences were extracted from Genbank using
BLAST 2.2.9 (NCBI). Mfold 3.2 (Washington Univer-
sity) was used to predict the stability of secondary RNA
structures. The most conserved regions were then
subjected to sequence analysis using the Primer 3 and
Oligo 6 (Molecular Biology Insights) softwares to design
primers and a probe [Rozen and Skaletsky, 2000].
Finally, the speciﬁcity of the primers and probe for
HEV genomes were tested by searching for homologous
sequences in Genbank using the Blast software.
Specimens
Two types of samples (RNAand clinical samples)were
tested by the real-time RT-PCR assay.
The ﬁrst type was composed of 52 HEV RNA pre-
parations from serum and stools provided by the French
National Reference Centre for hepatitis E. All 52 were
positive previously by conventional RT-PCR performed
at the FrenchNational Reference Centre for HEV at the
present time of the study. The HEV RNA samples were
stored at808C(Table I).HEVRNAof genotypes 1and2
had been ampliﬁedwith oligonucleotides targetingHEV
ORF2 (nt 6653–7100) as described elsewhere [Tam
et al., 1991]. HEV RNA of genotype 3 was detected by
conventional PCR using degenerate primers targeting
ORF1 andORF2 [Schlauder et al., 1999]. HEV genotype
4 RNA extracts, collected in Cambodia from humans
with sporadic cases of acute hepatitis and from swine,
were previously ampliﬁedwith primers forORF1 [Hsieh
et al., 1998].
The second type of specimens was composed of 120
human clinical samples, including 60 pairs of serumand
fecal samples collected during the hepatitis E outbreak
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Fig. 1. Sequence alignment within HEV ORF2 region of 26 complete HEV genomes and the plasmid
pSGI-HEV, and position of primers (TaqHEV-F and Taq HEV-R) and probe (TaqHEV-R). a: accession
number; sequences in white boldface were used for the consensus sequence for primers and probe.
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in Mornay Darfur, Sudan. The samples were collected
from members of the internally displaced population
presenting acute hepatitis in 2004 at the hospital camp,
then shipped to the French National Reference Centre
for Hepatitis E (cold chain transportþ48C) and tested.
Diagnosis of hepatitis E was conﬁrmed by detection of
anti-HEV IgG (HEV Elisa, Genlabs Diagnostic, Singa-
pore), anti-HEV IgM (HEV IgM Elisa, Genlabs Diag-
nostic) and molecular detection of HEV by conventional
HEV RT-PCR as described previously. A strong anti-
HEV IgG reactivity was found in 60/60 and anti-HEV
IgM in 55/60 serum, reﬂecting recent hepatitis E
infection. HEV RNA was ampliﬁed from 14 sera and
20 stools by conventional PCR [Tam et al., 1991]. The
sequencing of several PCR products generated by
conventional PCR indicated that genotype 1 was the
virus circulating in West Darfur (GenBank accession
number [AY903948]). Real-time TaqMan1 PCR was
used to quantify HEV RNA in these clinical samples.
Two serum samples collected from two anti-HEV-
negative, healthy subjects were used as negative
samples.
RNA Extraction and Reverse Transcription
RNA was extracted from clinical serum and stool
samples. One-tenth volume of 10 phosphate buffer
saline (PBS) was added to the stool samples and the
suspensions were mixed thoroughly and clariﬁed by
centrifugationat12,000gat roomtemperature for 2min.
Total RNA was then extracted from 200 ml samples of
sera and stool suspensions with the RNA Isolation kit I
(RocheDiagnosticsCorporation, Indianapolis, IN) using
the automated MagNA Pure device according to the
manufacturer’s recommendations. RNA was eluted in
100 ml of kit I elution buffer, aliquoted, and stored at
808Cuntil testing. Fivemicroliter samples of extracted
RNA were used for RT. RNA was ﬁrst incubated with
0.25 mg of oligo d(T)15 (in a ﬁnal volume of 8.5 ml) at 708C
for 5 min and immediately cooled on ice. Moloney
murine leukemia virus reverse transcriptase (M-MLV
Reverse Transcriptase) (Promega) was used for RT: a
ﬁnal volume of 12.5 ml of RT reaction containing
annealed primer/template (8.5 ml), 2.5 ml of 5M-MLV
buffer, 20 U of RNasin Plus Ribonuclease Inhibitor
(Promega), 200 U of M-MLV reverse transcriptase,
5 mM each of dATP, dCTP, dGTP, and dTTP, was
incubated in a Perkin-Elmer 9600 thermal cycler; the
cycling parameters were 5 min at 258C, 60 min at 428C,
15 min at 708C, followed by a 48C hold.
Real-Time Quantitative PCR With LightCycler
LightCycler-FastStart DNA Master hybridization
Probes (Roche Diagnostics) kit was used according to
themanufacturer’s instructions for real-time PCR. PCR
wasperformed inaﬁnal volumeof 15ml containing3mM
MgCl2, 0.3 mM of each HEV-speciﬁc primer, 0.2 mM of
internal probe, and 2 ml of the cDNA preparation. The
thermocycling conditions were optimized to one cycle of
denaturation for 10 min at 958C, followed by 50 ampli-
ﬁcation cycles (temperature transition rate of 58C/sec),
each cycle comprising denaturation (958C for 5 sec), and
annealing/extension (608C for 60 sec). Negative samples
and distilled water were tested in duplicate in each run
as negative controls.
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TABLE I. Fifty-Two HEV Clinical Isolates of the FourMajor Genotypes Provided by The French National Reference Centre for
Hepatitis E and Tested by Real-Time RT-PCR
Genotype Origin Specimens Travel history No. of strains
Genbank
accession number
Genotype 1 Human Stools Pakistan, India 6
Serum Tanefdur, Algeria 11 AY568365
AY596463
AY56836
AY568363
AY568362
AY568361
AY568360
AY596462
AY568359
AY568358
AY568357
Genotype 2 Human Stools Chad 4 DQ151637
AY903950
Serum Nigeria 5 AF 172999
AF 173000
AF 173001
AF 173230
AF 173231
Genotype 3 Human Stools No travel history (France) 6
Serum No travel history (France) 2
Genotype 4 Human Stools Cambodia 1
Serum Cambodia 1
Swine Stools Cambodia 15
Serum Cambodia 1
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Positive Control
The plasmid, pSGI-HEV containing a full-length
genotype 1 HEV cDNA [Panda et al., 2000], was used
as a DNA template in conventional PCR with sense and
antisense primers designed from the HEV strain
alignment: TaqHEV-F and TaqHEV-R. The resulting
PCR product was inserted into pGEM-T (Promega)
according to the manufacturer’s instructions. The
cloning region was sequenced and the recombinant
plasmid, named pGEM-HEVtaqm, was puriﬁed by the
MidiPrep Method (Qiagen) and was quantiﬁed with
the Gen Quant II instrument according to the manu-
facturer’s instructions (Pharmacia Biotech). Two
microliters of stock DNA contained 2.5 109 genome
equivalent (GE) copies of the plasmid. Serial 10-fold
dilutions of pGEM-HEVtaqmwereused as a standard to
establish the reference ampliﬁcation curve.
Controls and Interpretation
The linearity of the reference ampliﬁcation curve was
evaluated by ampliﬁcation of serial 10-fold dilutions of
the positive control pGEM-HEVtaqm induplicate in two
independent assays. Distilled water was used as a
negative control. The crossing point (Cp) was the
quantitative parameter and was determined by the
second derivative maximum (SDM) (LightCycler Soft-
ware 3.5.3). Samples with a Cp value below 43 and with
no evidence of ampliﬁcation in the negative control and
negative samples (threshold not reached after 45 cycles)
were considered as positive.
To check for the presence of contaminating DNA,
negative samples andnegative controlswere included in
each run of real time PCR. Experimental accuracy was
improved by running samples in duplicate startingwith
theRT reaction [Stahlberg et al., 2004] and the resulting
cDNA was subjected to two independent real-time PCR
assays.
RESULTS
Primer and Probe Design
The aimof the studywas to design a set of primers and
probe that would allow the detection of the four main
genotypes of HEV in a single real-time RT-PCR assay.
After collection of a set of 26 full-length HEV sequences
from Genbank, the sequences were compared and the
most conserved regions of HEV genome were thereby
identiﬁed. Three regions between nucleotides 1–150
(region I), 5000–5500 (region II), and6300–6500 (region
III) were selected and subjected to a more detailed
analysis. For each region, the most conserved sub-
regionswereﬁrst determined by extracting and compar-
ing all partial or complete HEV sequences available in
theGenbankdatabaseat the timeof the study.Then, the
sequences that met all the criteria required to design a
powerful consensus real-timeRT-PCRbased assaywere
identiﬁed. In particular, it was systematically excluded
sequences predicted to form highly stable secondary
RNA structures because such structures are likely to
impair primer annealing. A 86-bp region within ORF 2
(nt 5207–5292) appeared to be highly conserved and
suitable as the basis for a set of primers and probe for
real-time PCR, despite its GC nucleotide composition of
72% (Fig. 1). The sequences of the primers TaqHEV-F,
TaqHEV-R, and probe TaqHEV-S are shown in Table II.
Extensive search for homologous sequences in sequence
databases indicated that the primers and probe were
highly speciﬁc for HEV sequences.
Reference Ampliﬁcation Curve
and Detection Limit
The detection limit of the real-time PCR was evalu-
ated using serial 10-fold dilutions of pGEM-HEVtaqm, a
plasmid that contained the target DNA sequence
(Fig. 2). The assay had a linear response over at least a
9-log10 concentration range, from 10 to 10
9 copies/
reaction (R2¼0.998). The assay results were reproduci-
ble with a coefﬁcient of variation (CV) in the Cp values
range from 0.97% to 2.26% (mean of CV¼1.41%).
Efﬁciency and Reliability of
Real-Time HEV PCR
Aﬁrst set of experimentswas designed to determine if
the real-time RT-PCR assay was as sensitive as the
various conventional RT-PCR assays currently used to
detect the four major genotypes of HEV. The ability of
the real-time PCR assay to detect HEV RNA in 52 fecal
and serum samples of human and swine origin was
evaluated (Table I). All these samples were found
positive previously for HEV RNA on conventional RT-
PCRassaysperformedat theFrenchNationalReference
Centre for HEV. Independent of the genotype, all 52
samples gave ampliﬁcation products in the single real-
time RT-PCR assay (Cp values ranged from 28.02 to
35.4). No cross ampliﬁcation was observed.
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TABLE II. Primers and Probe Used for the Detection of HEV by Real-Time PCR Assay
Primer or probe Sequence (50-30) Location
TaqHEV-F GCCCGGTCAGCCGTCTGG 5207–5224b
TaqHEV-R CTGAGAATCAACCCGGTCAC 5273–5292b
TaqHEV-S FAM-CGGTTCCGGCGGTGGTTTCT-TAMRAa 5250–5269b
aThe probe was labeled with 6-carboxyﬂuorescein (FAM) at the 50 end and 6 carboxy-tetramethylrhoda-
mine (TAMRA) at the 30 end. It was designed so that the predicted melting temperature was at least 58C
higher than that of the primers.
bCorresponding nucleotide position of HEV virus (Burma) (accession no. M73218).
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Performance of Real-Time HEV PCR
From Clinical Samples
Preliminary experiments indicated that the real-time
RT-PCRassaywas as sensitive as conventional RT-PCR
assays. As the primers and probe were designed in a
highly conserved region, it was testedwhether this real-
time RT-PCR could detect HEV in samples from HEV-
infected patients that havenot been tested previously by
conventionalRT-PCRassays.Theperformances of these
two PCR methods were compared using a total of 120
samples comprising 60 pairs of serum and fecal samples
collectedbetween6and14days after the onset of clinical
signs of acute hepatitis. The serum samples were drawn
6–7 days after the onset of clinical signs for those with
high viral loads and over 7 days after the onset of signs
for those with lower viral loads. The fecal samples were
collectedbetween6and14days after the onset of clinical
signs.
The 120 samples were analyzed by both conventional
and real-time RT-PCR assays. Of the 120 samples, 34
samples (29%, 14 sera and 20 stools) were positive on
both assays. And real-time RT-PCR detected HEV in
additional samples (35 sera and 33 stools) with the
overall ampliﬁcation of 102 samples (85%) (49 sera and
53 stools) (Table III). The RT-PCR products of 33 stool
samples scoring positive by real-time RT-PCR and
negative by conventional RT-PCR were sequenced;
the presence of HEV virus was conﬁrmed. And the
sequences of these isolateswere identical to sequences of
samples positive on both assays. HEV real-time RT-
PCR-positive sampleswithCpvaluesbelow31 (7.2103
RNA copies/ml serum or mg stools) scored positive by
conventional RT-PCR.
The Cp values of sera only identiﬁed as positive by the
real-time RT-PCR assay were between 36.01 and 40.79,
corresponding to 6.15102–1.87 101 RNA copies/ml
serum. The Cp values of stool samples only identiﬁed as
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Fig. 2. Quantiﬁcation of serially diluted suspension (10–109 molecules) of quantiﬁed HEV plasmid
target obtained by real-time PCRwith LightCycler instrument using Taqman technology. a: Fluorescence
curve of F1/F2 signal formation during the ampliﬁcation of a 86 bp fragment of HEV gene (each point
represents the mean of the Cp from four independent assays. CV, coefﬁcient of variation); (b) standard
curve constructed form the date in (a).
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positive by real-time RT-PCR assay were between 33
and 41 corresponding to 1.15103–1.51101 RNA
copies/mg stool. These results based on a genotype 1
standard (pGEM-HEVtaqm) conﬁrmed that conven-
tional PCR-based assays used in this study were less
sensitive than the single real-time RT-PCR.
The reproducibility of these data was assessed by
testing each sample in duplicate.
DISCUSSION
Real-time nucleic acid ampliﬁcation systems are
reliable tools with high sensitivity and speciﬁcity, and
fast turnaround times. The idea of performing both the
RTandPCR in a single tube is attractive since it reduces
handling and therefore minimizes the chance of pipet-
ting errors and contamination. Unlike Jothikumar et al.
[2006], a two-step RT-PCRmethod was used to compare
results of conventional and real-timePCRwith the same
cDNA and moreover it was found that the one-step
method is variable intrinsically and signiﬁcantly less
sensitive than the two-step method. Many researchers
have reported these conclusions and it was shown that
experimental variation in RT-PCR is attributable
mainly to the RT step [Battaglia et al., 1998; Bustin,
2002; Stahlberg et al., 2004]. Jothikumar et al. [2006]
describedaTaqMan1RT-PCRassayevaluatedwith few
HEV isolates tested previously from four major geno-
types. The present development of a single consensus
real-time TaqMan1RT-PCRhas the advantage of being
validated with RNA extracts from clinical samples (sera
and stools) for all the four major genotypes of HEV.
Moreover, quantitation of viral loads in serum and fecal
specimens indicated that this real-time RT-PCR assay
had a detection limit 10- to 100-fold lower than for
conventional RT-PCR assays used in this study.
The main difﬁculty when developing a molecular
assay forHEVvirus is the design and construction of the
primers and probe: they must be compatible with the
genetic heterogeneity of this virus and the high GþC
content of the viral genome. Because of the process, it
was used to identify the most conserved regions of the
viral genome. And two different set of primers were
determined from nt 5260–5330 [Jothikumar et al.,
2006] within ORF3 HEV region and from 5207 to 5292
within ORF2 HEV region in the present study. It is
likely that this RT-PCR assay detects a broader set of
genotypes. This, however, remains to be assessed.
An advantage of real-time RT-PCR is the improve-
ment in the diagnosis of hepatitis E. The course of HEV
infection is monitored currently by RT-PCR assays with
samples collected during outbreaks of hepatitis E and
from experimentally infected animals. With conven-
tional RT-PCR, HEVRNA can be detected in serum and
stools from most patients within 2 weeks [Clayson
et al., 1995]. A study with sequential serum and stools
collected frompatients during an outbreakof hepatitisE
reported viraemia until day 29 and fecal excretion until
day 35; this is longer than both the clinical course and
the duration of biochemical hepatitis [Aggarwal et al.,
2000]. Suitable real-time RT-PCR may allow the dura-
tion of viraemia and fecal shedding to be determined
more rigorously. Indeed, further analyses of sequential
samples are required to determine the duration of
infectiousness. HEV infections have been described in
the absence of anti-HEV IgG and IgM [Nicand et al.,
2001;Mansuy et al., 2004b]: the singleHEVmarkerwas
HEV RNA either in serum or in stools. Using this
powerful technique, such infectionswithavery lowHEV
loads (102 HEV molecules per reaction) could be
detected.
The real-time TaqMan1 PCR assay able to detect any
genotype of HEV opens new opportunities. This sensi-
tive method should allow HEV to be quantiﬁed in
environmental samples, particularly water sources.
Outbreaks, like the recent outbreak in the Western
Darfur region of Sudan, were likely to have been
associated with water supplies [Nicand et al., 2005].
It is concluded that the consensus real-time RT-PCR
assay developed in this work is a highly sensitive and
speciﬁc tool for accurate quantiﬁcation of major geno-
types ofHEVvirus. This assaywill be useful as a routine
diagnostic assay for clinical specimens.
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